Nano Nuclear Energy Inc. Files S-1 with SEC

TL;DR

Nano Nuclear Energy Inc. just filed its S-1. Check financials and future plans.

AI Summary

Nano Nuclear Energy Inc. filed an S-1 form on July 9, 2024, detailing its business operations and financial status. The company, incorporated in Nevada, is involved in the electric services sector and has its principal executive offices at 10 Times Square, New York, NY. The filing covers financial periods up to March 31, 2024, and includes information on its equity structure, such as common stock and additional paid-in capital.

Why It Matters

This S-1 filing provides crucial insights into Nano Nuclear Energy Inc.'s financial health and strategic direction, which is important for investors and stakeholders evaluating the company's future prospects in the energy sector.

Risk Assessment

Risk Level: medium — As a company filing an S-1, it is likely in the process of going public or raising capital, which inherently carries higher risks than established public companies.

Key Numbers

• 20240709 — Filing Date (Date the S-1 form was filed with the SEC.)
• 0930 — Fiscal Year End (Indicates the end of the company's fiscal year.)
• 2024-03-31 — Latest Financial Period End (The most recent financial reporting date included in the filing.)

Key Players & Entities

• Nano Nuclear Energy Inc. (company) — Filer of the S-1 document
• 0001923891 (company) — Central Index Key for Nano Nuclear Energy Inc.
• 4911 (company) — Standard Industrial Classification code for Electric Services
• NV (company) — State of incorporation
• 10 Times Square, 30th Floor, New York, NY 10018 (company) — Business and mailing address
• 6046875792 (company) — Business phone number
• 333-280727 (dollar_amount) — SEC file number
• 241106265 (dollar_amount) — Film number

FAQ

Key Financial Figures

• $23.80 — ) based on an assumed offering price of $23.80 per Unit, which was the last reported s
• $1,207,502 — writing discounts will be approximately $1,207,502 and the additional proceeds to us, befo
• $2,070,004 — t option exercise will be approximately $2,070,004. The underwriters expect to deliver t
• $1 million — anticipate would require approximately $1 million over the next twelve months to recruit
• $8 million — imated expenditures to be approximately $8 million. This allocation comprises approximatel
• $6 million — This allocation comprises approximately $6 million dedicated to the research and developme
• $2 million — manufacturing processes. The remaining $2 million is earmarked for miscellaneous costs es
• $10,273,798 — have incurred accumulated net losses of $10,273,798 since inception through March 31, 2024.

Filing Documents

• forms-1.htm (S-1) — 2309KB
• ex1-1.htm (EX-1.1) — 271KB
• ex4-2.htm (EX-4.2) — 85KB
• ex4-3.htm (EX-4.3) — 239KB
• ex5-1.htm (EX-5.1) — 33KB
• ex23-1.htm (EX-23.1) — 3KB
• ex107.htm (EX-FILING FEES) — 42KB
• formdrs_001.jpg (GRAPHIC) — 7KB
• formdrs_002.jpg (GRAPHIC) — 20KB
• formdrs_003.jpg (GRAPHIC) — 12KB
• formdrs_004.jpg (GRAPHIC) — 12KB
• formdrs_005.jpg (GRAPHIC) — 15KB
• formdrs_006.jpg (GRAPHIC) — 14KB
• formdrs_007.jpg (GRAPHIC) — 14KB
• formdrs_008.jpg (GRAPHIC) — 17KB
• formdrs_009.jpg (GRAPHIC) — 15KB
• formdrs_010.jpg (GRAPHIC) — 19KB
• formdrs_011.jpg (GRAPHIC) — 14KB
• formdrs_012.jpg (GRAPHIC) — 14KB
• formdrs_013.jpg (GRAPHIC) — 14KB
• formdrs_014.jpg (GRAPHIC) — 17KB
• ex5-1_001.jpg (GRAPHIC) — 2KB
• 0001493152-24-026556.txt ( ) — 7144KB
• nne-20240331.xsd (EX-101.SCH) — 23KB
• nne-20240331_cal.xml (EX-101.CAL) — 31KB
• nne-20240331_def.xml (EX-101.DEF) — 127KB
• nne-20240331_lab.xml (EX-101.LAB) — 236KB
• nne-20240331_pre.xml (EX-101.PRE) — 177KB
• forms-1_htm.xml (XML) — 706KB

Underwriting

Underwriting discounts (1) $ $ Proceeds to us, before expenses (2) $ $ (1) Represents underwriting discounts equal to (i) seven percent (7%) per Unit (or $[ ] per Unit), which is the underwriting discounts we have agreed to pay to the underwriters. (2) Does not include a non-accountable expense allowance equal to one percent (1%) of the gross proceeds of this offering, payable to the representative of the underwriters, or the reimbursement of certain expenses of the underwriters. We have also agreed to issue warrants to the representative of the underwriters to purchase a number of shares of common stock equal to seven percent (7%) of the total number of shares of common stock included as part of the Units sold in this offering at an exercise price equal to one hundred and twenty-five percent (125%) of the public offering price of the Units sold in this offering. For a description of the other terms of compensation to be received by the underwriters, see " Underwriting ." We have granted a 30-day option to the representative of the underwriters to purchase up to an additional 94,538 shares of common stock and/or additional Warrants to purchase up to 47,269 shares of common stock solely to cover over-allotments, if any. If the representative of the underwriters exercises the option in full, the total underwriting discounts will be approximately $1,207,502 and the additional proceeds to us, before expenses, from the over-allotment option exercise will be approximately $2,070,004. The underwriters expect to deliver the Units to purchasers on or about [], 2024. The Benchmark Company The date of this prospectus is [], 2024 Creating the Next Generation of Advanced Nuclear Fuels and Developing Smaller, Cheaper and Safer Portable Clean Energy Solutions Renderings of proposed "Zeus" Microreactor Renderings of proposed "Odin" Microreactor Proposed HALEU Fuel Fabrication Facility TABLE OF CONTENTS PAGE PROSPECTUS SUMMARY 1 THE OFFERING 11

USE OF PROCEEDS

USE OF PROCEEDS 37 DIVIDEND POLICY 37 CAPITALIZATION 38

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 41

BUSINESS

BUSINESS 48 MANAGEMENT 70 EXECUTIVE AND DIRECTOR COMPENSATION 79 PRINCIPAL STOCKHOLDERS 84 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 8 5

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 86 SHARES ELIGIBLE FOR FUTURE SALE 91 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 93

UNDERWRITING

UNDERWRITING 97 LEGAL MATTERS 101 EXPERTS 101 WHERE YOU CAN FIND ADDITIONAL INFORMATION 101 INDEX TO FINANCIAL STATEMENTS F-1 You should only rely on the information contained in this prospectus and in any free writing prospectus prepared by or on behalf of us and delivered or made available to you. Neither we nor the underwriters have authorized anyone to provide you with additional or different information. We are offering to sell, and seeking offers to buy, Units only in jurisdictions where offers and sales are permitted. The information contained in this prospectus or a free writing prospectus is accurate only as of its date, regardless of its time of delivery or of any sale of the Units. Our business, financial condition, operating results, and prospects may have changed since that date. For investors outside the United States : Neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United restrictions relating to, the offering of the Units, and the distribution of this prospectus outside of the United States. i INDUSTRY AND MARKET DATA Unless otherwise indicated, information in this prospectus concerning economic conditions, our industry, our markets and our competitive position is based on a variety of sources, including information from third-party industry analysts and publications and our own estimates and research. Some of the industry and market data contained in this prospectus are based on third-party industry publications. This information involves a number of assumptions, estimates and limitations. The industry publications, surveys and forecasts and other public information generally indicate or suggest that their information has

View Full Filing

View this S-1 filing on SEC EDGAR